Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial

Robert B. M. Landewe, Jos G. A. Houbiers, Filip van de Bosch, Joanna in't Hout, Patrick C. P. M. Verschueren, Jan H. Meijerink, Frank H. J. van den Hoogen, Bedrich A. Masek, George A. W. Bruyn, Jacques M. G. W. Wouters, Alexandre E. Voskuyl, Jacob M. van Laar, Johannes W J Bijlsma, Desiree M. F. M. van der Heijde, Ferdinand C. Breedveld, Leo B. A. van de Putte, Andre M. M. Miltenburg, Filip De Keyser

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1655-1659
JournalAnnals of the Rheumatic Diseases
Volume69
Issue number9
DOIs
Publication statusPublished - Sep 2010

Cite this

Landewe, R. B. M., Houbiers, J. G. A., van de Bosch, F., in't Hout, J., Verschueren, P. C. P. M., Meijerink, J. H., van den Hoogen, F. H. J., Masek, B. A., Bruyn, G. A. W., Wouters, J. M. G. W., Voskuyl, A. E., van Laar, J. M., Bijlsma, J. W. J., van der Heijde, D. M. F. M., Breedveld, F. C., van de Putte, L. B. A., Miltenburg, A. M. M., & De Keyser, F. (2010). Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial. Annals of the Rheumatic Diseases, 69(9), 1655-1659. https://doi.org/10.1136/ard.2009.117234